Clinical Trial Update: A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety, tolerability, and biomarker signals of VS-041 in participants with heart failure with preserved ejection fraction (HFpEF) i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• VS-041

Snippet

Sponsor: Vasa Therapeutics | Conditions: Heart, Heart Failure With Preserved Ejection Fraction (HFPEF) | Phase 1 | Status: RECRUITING